|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administration_duration
|
30 minutes
|
|
gptkbp:administration_setting
|
gptkb:hospital
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
gptkb:United_States
positive
Phase 3
randomized controlled trials
published in journals
various sites globally
multiple phases conducted
Uro Gen Pharma
|
|
gptkbp:clinical_trial_endpoints
|
overall survival
|
|
gptkbp:collaborations
|
academic institutions
various institutions
|
|
gptkbp:competitors
|
other bladder cancer treatments
|
|
gptkbp:customer_satisfaction
|
assessed through surveys
|
|
gptkbp:developed_by
|
Uro Gen Pharma
|
|
gptkbp:distribution
|
managed by Uro Gen Pharma
|
|
gptkbp:dosage_form
|
weekly for 6 weeks
|
|
gptkbp:drug_interactions
|
limited
|
|
gptkbp:duration
|
6 weeks
|
|
gptkbp:eligibility
|
specific criteria
|
|
gptkbp:fdaapproval_status
|
approved
|
|
gptkbp:feedback
|
collected for improvement
|
|
gptkbp:financial_support
|
available through Uro Gen Pharma
|
|
gptkbp:formulation
|
hydrogel
|
|
gptkbp:funding
|
gptkb:venture_capital
|
|
gptkbp:grants
|
obtained for further studies
|
|
gptkbp:has_membership
|
to specialists for treatment
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Uro Gen's RTGel
|
|
gptkbp:ingredients
|
mitomycin
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
regular follow-ups
|
|
gptkbp:launch_date
|
gptkb:2020
|
|
gptkbp:manufacturing_process
|
GMP compliant
|
|
gptkbp:marketed_as
|
gptkb:brand
|
|
gptkbp:mechanism_of_action
|
chemotherapy agent
|
|
gptkbp:patient_compliance
|
critical for success
|
|
gptkbp:patient_education
|
important for treatment success
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:post_treatment_monitoring
|
cystoscopy
|
|
gptkbp:price
|
considered high
|
|
gptkbp:provides_guidance_on
|
available in select markets
updated regularly.
included in treatment protocols
|
|
gptkbp:publication
|
peer-reviewed journals
|
|
gptkbp:recruitment
|
ongoing for trials
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
|
|
gptkbp:research_areas
|
bladder cancer therapies
|
|
gptkbp:research_focus
|
oncology
|
|
gptkbp:route_of_administration
|
intravesical
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
once per week
|
|
gptkbp:shipping_options
|
direct instillation
|
|
gptkbp:side_effect
|
local irritation
reported in clinical trials
|
|
gptkbp:supply_chain
|
managed by Uro Gen Pharma
|
|
gptkbp:targets
|
urothelial carcinoma
|
|
gptkbp:training
|
necessary for administration
|
|
gptkbp:treatment
|
evaluated in studies
tumor reduction
monitored post-treatment
assessed by clinical trials
standardized for trials
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by provider
|
|
gptkbp:used_for
|
treatment of bladder cancer
|
|
gptkbp:bfsParent
|
gptkb:Uro_Gen
|
|
gptkbp:bfsLayer
|
6
|